SD-101 failed a major skin disease trial. Can Paradigm’s new Phase 3 study change its future?
Paradigm Therapeutics has received its second consecutive Prix Galien USA nomination for SD-101, an investigational whole-body epidermolysis bullosa cream. A new pediatric Phase 3 study offers another opportunity to establish efficacy after the earlier ESSENCE trial failed its primary endpoints.
